Reuters: Regulatory News: Gilead, Teva reach settlement in Viread patent lawsuit

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Gilead, Teva reach settlement in Viread patent lawsuit Feb 20th 2013, 04:27 Tue Feb 19, 2013 11:27pm EST Feb 19 (Reuters) - Gilead Sciences Inc said it has agreed with Israel's Teva Pharmaceuticals Industries Ltd to settle a lawsuit relating to patents protecting Viread, a treatment for HIV infection and chronic hepatitis B. As per the agreement, Gilead said Teva will be allowed to launch a generic version of Viread on Dec. 15, 2017. "This settlement removes some uncertainty and minimizes further distraction and investment of human and financial resources associated with this litigation," Gilead's chief operating officer, John Milligan, said in a statement late on Tuesday. Gilead, based in California, is the world's largest maker of branded drugs to treat the human immunodeficiency virus, the cause of AIDS. The trial in the lawsuit, which was scheduled to begin on Feb. 20 in a Manhattan court, has been adjourned to finalize the settlement, Gilead said.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions